van den Berg Eline H, van Tienhoven-Wind Lynnda J N, Amini Marzyeh, Schreuder Tim C M A, Faber Klaas Nico, Blokzijl Hans, Dullaart Robin P F
Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, The Netherlands.
Department of Endocrinology, University of Groningen and University Medical Center Groningen, The Netherlands.
Metabolism. 2017 Feb;67:62-71. doi: 10.1016/j.metabol.2016.11.002. Epub 2016 Nov 6.
Overt hypothyroidism confers an increased risk of non-alcoholic fatty liver disease (NAFLD). The liver plays a crucial role in the metabolism of cholesterol and triglycerides; thyroid hormones interact on hepatic lipid homeostasis. Thyroid function within the euthyroid range affects a number of health issues, including atherosclerosis development and biochemical markers of increased cardiovascular risk. However, the association of thyroid hormones with NAFLD in euthyroid subjects has not been unequivocally established. We therefore determined associations of thyroid hormone parameters with NAFLD among euthyroid subjects.
The study was conducted in the Lifelines Cohort Study, a population-based cohort study of participants living in the North of the Netherlands. Only euthyroid subjects (thyroid-stimulating hormone (TSH) 0.5-4.0mU/L, free thyroxine (FT4) 11-19.5pmol/L and free triiodothyronine (FT3) 4.4-6.7pmol/L) older than 18years were included. Exclusion criteria were participants with excessive alcohol use, known hepatitis or cirrhosis, liver functions ≥ three times the upper limit, current cancer, non-white ancestry, previous or current use of thyroid medication and current use of lipid or glucose lowering medication. A priori defined liver biochemistry, thyroid function parameters and metabolic syndrome (MetS) were studied. NAFLD was defined by using the validated Fatty Liver Index (FLI); FLI≥60 was categorized as NAFLD. A P<0.01 was considered significant.
FLI≥60 was found in 4274 (21.1%) of 20,289 individuals (62.1% male, median age 46years) with increased prevalence of MetS (P<0.0001). In age- and sex-adjusted analysis FLI≥60 was independently associated with a higher FT3 (OR 1.34, 95% CI 1.29-1.39, per SD increment, P<0.0001) and a lower FT4 (OR 0.73, 95% CI 0.70-0.75, P<0.0001) but not by TSH. The strongest association was found for the FT3/FT4 ratio (OR 1.44, 95% CI 1.39-1.49, P<0.0001). These associations remained similar after additional adjustment for the presence of MetS. In subjects with enlarged waist circumference, TSH and FT4 were lower while FT3 was higher, resulting in an increased FT3/FT4 ratio (P<0.0001).
Euthyroid subjects with suspected NAFLD are characterized by higher FT3, lower FT4 and higher FT3/FT4 ratio, probably consequent to central obesity.
显性甲状腺功能减退会增加非酒精性脂肪性肝病(NAFLD)的风险。肝脏在胆固醇和甘油三酯的代谢中起关键作用;甲状腺激素对肝脏脂质稳态有影响。甲状腺功能在正常范围内会影响许多健康问题,包括动脉粥样硬化的发展以及心血管风险增加的生化标志物。然而,甲状腺激素与甲状腺功能正常的受试者中NAFLD的关联尚未明确确立。因此,我们确定了甲状腺激素参数与甲状腺功能正常的受试者中NAFLD的关联。
该研究在生命线队列研究中进行,这是一项针对居住在荷兰北部的参与者的基于人群的队列研究。仅纳入年龄大于18岁的甲状腺功能正常的受试者(促甲状腺激素(TSH)0.5 - 4.0mU/L,游离甲状腺素(FT4)11 - 19.5pmol/L,游离三碘甲状腺原氨酸(FT3)4.4 - 6.7pmol/L)。排除标准为过度饮酒者、已知患有肝炎或肝硬化者、肝功能≥正常上限三倍者、当前患有癌症者、非白种人血统者、既往或当前使用甲状腺药物者以及当前使用降脂或降糖药物者。研究了预先定义的肝脏生化指标、甲状腺功能参数和代谢综合征(MetS)。使用经过验证的脂肪肝指数(FLI)定义NAFLD;FLI≥60被归类为NAFLD。P<0.01被认为具有统计学意义。
在20289名个体(62.1%为男性,中位年龄46岁)中,有4274名(21.1%)的FLI≥60,MetS患病率增加(P<0.0001)。在年龄和性别调整分析中,FLI≥60与较高的FT3(OR 1.34,95%CI 1.29 - 1.39,每标准差增加,P<0.0001)和较低的FT4(OR 0.73,95%CI 0.70 - 0.75,P<0.0001)独立相关,但与TSH无关。发现FT3/FT4比值的关联最强(OR 1.44,95%CI 1.39 - 1.49,P<0.0001)。在对MetS的存在进行额外调整后,这些关联仍然相似。在腰围增大的受试者中,TSH和FT4较低,而FT3较高,导致FT3/FT4比值增加(P<0.0001)。
疑似患有NAFLD的甲状腺功能正常的受试者的特征是FT3较高、FT4较低和FT3/FT4比值较高,这可能是中心性肥胖所致。